APLS logo Apellis Pharmaceuticals : APLS

APLS

Stock Data

$40.96

Change up

$0.01 (0.02%)

Asset Type

Common Stock

Exchange

NASDAQ

Currency

USD

Country

USA

Sector

HEALTHCARE

Industry

BIOTECHNOLOGY

Apellis Pharmaceuticals Inc is a pioneering biopharmaceutical firm dedicated to developing innovative treatments for autoimmune and inflammatory diseases by targeting the complement system. Its flagship product, EMPAVELI, is designed for various conditions including paroxysmal nocturnal hemoglobinuria and C3 glomerulopathy. Apellis is also advancing SYFOVRE for age-related macular degeneration and has other promising therapies in early-stage trials. Founded in 2009 and headquartered in Waltham, Massachusetts, the company collaborates with industry leaders to enhance its drug development pipeline.

All Apellis Pharmaceuticals Articles

13 Articles

Featured Reads

Our top personal finance-related articles today. Your wallet will thank you later.